How effective is Erleada (apalutamide)?
Erleada (apalutamide) is used for nonmetastatic castration-resistant prostate cancer (nmCRPC) and for metastatic, castration-sensitive prostate cancer (mCSPC).
Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
The SPARTAN clinical trial (NCT01946204) for nmCRPC studied how effective Erleada was at increasing the time before prostate cancer had spread to other parts of the body, or time before death occurred. Patients who were in the apalutamide group had a median metastasis-free survival 24.3 months longer before cancer spread to other parts of the body or before death occurred, when compared to the placebo group.
The median metastasis-free survival for nmCRPC was:
- 40.5 months in the apalutamide group
- 16.2 months in the placebo group
- This means the apalutamide group of patients lived a median of 24.3 months longer without progressing to metastasis or death (40.5 -16.2= 24.3 months).
Metastatic, Castration-Sensitive Prostate Cancer (mCSPC).
The TITAN clinical trial (NCT02489318) for mCSPC looked at whether the addition of apalutamide to androgen-deprivation therapy (ADT) would increase radiographic progression–free survival and also increase overall survival, when compared with placebo plus ADT. Radiographic progression–free survival is the length of time before imaging shows cancer has progressed or death occurs.
Radiographic progression–free survival
The results of the TITAN trial show that at 24 months the percentage of mCSPC patients with radiographic progression–free survival was:
- 68.2% in the apalutamide + ADT group
- 47.5% in the placebo + ADT group
- Meaning the apalutamide + ADT group had 20.7% more patients who reached 24 months without radiographic progression of their cancer. (68.2%-47.5%=20.7%)
Overall survival
Effectiveness of apalutamide on mCSPC was also measured by overall survival in each group after 24 months:
- 82.4% in the apalutamide + ADT group were still alive
- 73.5% in the placebo + ADT group were still alive
- This means that after 24 months there were more patients surviving in the apalutamide + ADT group compared to the placebo + ADT group.
Bottom line:
- Nonmetastatic castration-resistant prostate cancer (nmCRPC) patients on apalutamide lived a median of 24.3 months longer without progressing to metastasis or death (40.5 - 16.2 = 24.3 months) when compared to the placebo group.
- A larger percentage of metastatic, castration-sensitive prostate cancer (mCSPC) patients on apalutamide + ADT reached 24 months without radiographic progression of their cancer, compared to the placebo + ADT group.
- More of the metastatic, castration-sensitive prostate cancer (mCSPC) patients in the apalutamide + ADT treatment group were still alive after 24 months, compared to placebo + ADT group.
Related questions
References
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa1715546
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer: https://www.nejm.org/doi/full/10.1056/nejmoa1903307
- Erleada Professional Information: https://www.drugs.com/pro/erleada.html
Read next
Why has Xtandi stopped working and what do I take next?
Prostate cancer cells, like bacteria, can evolve over time and become resistant to treatments, including the hormone therapy and androgen receptor inhibitor Xtandi (enzalutamide). The cancer cells work to reprogram their environment and develop strategies that enable them to transform and survive.
If treatment with Xtandi stops working then other treatments may be offered, such as:
- Chemotherapy
- Immunotherapy
- Targeted therapy
- Radiotherapy
Stopping treatment with Xtandi may also result in an antiandrogen withdrawal response (AAWR), which can cause the cancer to stop growing or shrink for the period of time. Continue reading
How long does Xtandi work?
Xtandi is typically taken until prostate cancer starts to progress or spread (metastasize), or until the patient can no longer tolerate therapy because of the side effects or adverse events it causes.
In clinical trials, Xtandi was effective at delaying the time to disease progression in men with advanced prostate cancer. In men who had not received prior treatment with chemotherapy, Xtandi was also effective at delaying the need for treatment with a cytotoxic chemotherapy agent.
In the AFFIRM trial, treatment with Xtandi extended life by almost 5 months in men with metastatic castration-resistant prostate cancer. Continue reading
How long do you take Orgovyx for?
Orgovyx (relugolix) is taken once daily for as long as it remains effective and side effects are manageable. Prostate cancer often requires long-term hormone control, and studies show Orgovyx can be used safely for up to 48 weeks. Continue reading
Related medical questions
- What type of prostate cancer is Erleada used to treat?
- What type of cancer is Rubraca used to treat?
- What medications can increase PSA levels?
- Why is prednisone prescribed with Zytiga?
- How long do you take Zytiga for?
- Xtandi vs Zytiga: How do they compare?
- What happens when you stop taking Casodex?
- How long should you take Eligard for?
- Are Lupron Depot and Eligard the same drug?
- How long should you take Casodex for?
- Can you get pregnant on Lupron Depot?
- Does Xtandi lower prostate-specific antigen (PSA)?
- Is Zytiga a form of chemotherapy?
- Is Lupron Depot a chemotherapy treatment?
- How effective is Casodex for prostate cancer?
- How long does it take Lynparza (olaparib) to work?
- Is Firmagon (degarelix) the same as Lupron?
- How do you inject Lupron Depot for prostate cancer?
- How is Eligard injected / administered for prostate cancer?
- Is Eligard a chemotherapy drug?
- How effective is Lynparza (olaparib)?
- What does abiraterone therapy do?
- How long does it take for Degarelix to work?
- What's the difference between Yonsa and Zytiga?
Drug information
Related support groups
- Erleada (6 questions, 5 members)
- Apalutamide (4 questions, 5 members)
- Prostate Cancer (59 questions, 158 members)